Clinical Trials Logo

Clinical Trial Summary

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3804 in patients with advanced malignant tumors.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04128085
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Wu yilong, Doctor
Phone 020-83877557
Email syylwu@live.cn
Status Recruiting
Phase Phase 1
Start date November 15, 2019
Completion date October 2021

See also
  Status Clinical Trial Phase
Completed NCT05082545 - Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05229497 - A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT06223841 - A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Not yet recruiting NCT05728541 - Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05354076 - Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo Phase 2
Recruiting NCT05868876 - A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05991583 - A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05396391 - A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05235542 - A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05110807 - A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05214482 - A Study of AK112 in Advanced Malignant Tumors Phase 1/Phase 2
Not yet recruiting NCT05653284 - A Study of AK130 in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05223231 - Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors Phase 1/Phase 2
Enrolling by invitation NCT05198817 - A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients Phase 1
Active, not recruiting NCT05193721 - A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors Phase 1
Not yet recruiting NCT06226363 - Phase I Study of LNF1901 in Advanced Malignant Tumors Phase 1
Recruiting NCT06167486 - SG2918 For Advanced Malignant Tumors Phase 1
Recruiting NCT04980690 - Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Recruiting NCT05877924 - A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. Phase 1
Active, not recruiting NCT04708210 - Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors Phase 1